Abstract
Purpose
To identify key factors for successful integration of translational science into cancer care.
Results
Organisation of the health care system matters to optimally bridge between public and private cancer research, cancer registries and routine care. Currently, there are deficits on various levels of connectivity. These hamper rapid and optimal transfer of innovation.
Conclusion
To overcome the deficits, strategies of data sharing and infrastructures allowing fast-track implementation of translational research findings into routine care need to be developed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
https://www.sciencedirect.com/journal/european-journal-of-cancer/special-issue/10CBVRJ1DGD
Ortmann O, Helbig U, Torode J (2016a) Improving cancer care in Europe: which institutional health structures might be beneficial and why? 1. European Roundtable Meeting (ERTM), 16th May 2014, Berlin, Germany. J Cancer Res Clin Oncol. 142(1):1–4. https://doi.org/10.1007/s00432-014-1906-x (Epub 2015 Feb 3)
Ortmann O, Torode J, Helbig U (2016b) Improving structural development in oncology: transformation of theoretical health care standards and knowledge into a practical approach—2nd European Roundtable Meeting (ERTM), May 8, 2015, Berlin. Germany. J Cancer Res Clin Oncol 142(4):807–811. https://doi.org/10.1007/s00432-015-2052-9 (Epub 2015 Oct 19)
Ortmann O, Helbig U, Rösler W (2017) Current developments in cancer care: including the patients’ perspective—3rd European Roundtable Meeting (ERTM) June 17, 2016, Berlin, Germany. J Cancer Res Clin Oncol 143(4):673–676. https://doi.org/10.1007/s00432-016-2320-3 (Epub 2016 Dec 17)
Ortmann O, Helbig U, Torode J, Schreck S, Karjalainen S, Bettio M, Ringborg U, Klinkhammer-Schalke M, Bray F (2018) Quality control and improvement of cancer care—what is needed? 4th European Roundtable Meeting (ERTM) May 5th, 2017, Berlin. Germany. J Cancer Res Clin Oncol 144:1097–1102
Acknowledgements
List of all participants: Europe/Association of European Cancer Leagues: Nicolas Philippou, Board member of the Association of European Cancer Leagues, Chief Executive, The Cyprus Association of Cancer Patients and Friends, Nicosia, Cyprus. European Commission: Dr. Stefan Schreck, Chef d’unité, Programme santé et maladies chroniques, Direction générale de la santé et sécurité alimentaire, Luxembourg. Slovenia: Prof. Dr. Tit Albreht, Head of the Centre for Health Care—National Institute of Public Health, Lubljana. Spain: Prof. Dr. Josep Borras, Scientific Coordinator Spanish Cancer, Director, Catalonian Cancer Strategy, Hospital Duran I Reynals, Barcelona. Global/Union of International Cancer Control: Dr. Julie Torode, Deputy CEO, Advocacy and Networks Director, Union for International Cancer Control (UICC), Geneva. The Netherlands: Prof. Dr. Jan-Willem Coebergh, former Head of the section Cancer Surveillance of the Department of Public Health, Erasmus MC Rotterdam and of Research at the Comprehensive Cancer Centre South (IKZ) Eindhoven. United Kingdom: Prof. Chris Harrison, National Clinical Director for Cancer, NHS England, Medical Director (Strategy), The Christie NHS Foundation Trust, Manchester. Germany: Dr. Johannes Bruns, Secretary-General of the German Cancer Society, Berlin, Dr. Ulrike Helbig MBA, General Manager Section A, German Cancer Society, Berlin, Prof. Dr. Andreas Hochhaus, Board Member of the German Cancer Society, Director Dept. Haematology and Clinical Oncology, Director of the University Tumor Centre Jena, PD Dr. Monika Klinkhammer-Schalke, Director Tumor Centre Regensburg, Managing Board Member German Tumor Centres Work Group, Berlin, Dr. Christoph Kowalski, Research Coordination Certification, German Cancer Society, Berlin, Prof. Dr. Margarete Landenberger, Institute of Health and Nursing Science, Medical Faculty of Martin-Luther University Halle-Wittenberg, Halle (Saale), Dr. Katrin Mugele, Press officer, German Cancer Society, Berlin, Prof. Dr. Olaf Ortmann, President of the German Cancer Society, Director Department Gynaecology and Obstetrics, University Medical Center, Caritas-Hospital St. Josef, Regensburg, Ralf Rambach, Director of the Board, Haus der Krebsselbsthilfe Bundesverband e. V., Bonn.
Funding
No funding was received.
Author information
Authors and Affiliations
Consortia
Contributions
OO: manuscript writing, editing. JT: manuscript writing, editing. CH: manuscript writing, editing. JB: manuscript writing, editing. UH: manuscript writing, editing.
Corresponding author
Ethics declarations
Conflict of interest
Author O. Ortmann M.D. declares that he has no conflict of interest. Author J. Torode declares that she has no conflict of interest. Author C. Harrison declares that he has no conflict of interest. Author J. Bruns declares that he has no conflict of interest. Author U. Helbig M.D. declares that she has no conflict of interest.
Human and animal rights statement
This article does not contain any studies with human participants or animals performed by any of the authors.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The members of the Participants of the ERTM are listed in Acknowledgements.
Rights and permissions
About this article
Cite this article
Ortmann, O., Torode, J., Harrison, C. et al. Research driving innovation: what are key factors for successful integration of translational science into oncology care concepts? 5th European Roundtable Meeting (ERTM) May 4th, 2018, Berlin, Germany. J Cancer Res Clin Oncol 145, 1521–1525 (2019). https://doi.org/10.1007/s00432-019-02916-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-019-02916-0